Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
07 April 1994Website:
http://acceleratediagnostics.comNext earnings report:
28 March 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 15 Nov 2024 14:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
AXDX Latest News
Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Laura Pierson - Investor Relations Officer Jack Phillips - President and Chief Executive Officer David Patience - Chief Financial Officer Conference Call Participants Operator Good day, and welcome to the Accelerate Diagnostics Inc. Third Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.92 per share a year ago.
TUCSON, Ariz. , Oct. 25, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced that management will host a conference call Thursday, November 7, 2024, at 4:30 p.m.
AXDX's Arc system gains FDA clearance, automating blood culture prep for faster microbial ID, improved sepsis outcomes and reduced hospital costs.
An automated platform designed to fight against Sepsis and Antimicrobial Resistance (AMR) Enables rapid, automated microbial identification on the Bruker MALDI Biotyper® CA System directly from positive blood culture samples TUCSON, Ariz. , Sept. 30, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX), an innovator of rapid in vitro diagnostics, announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the Accelerate Arc system and BC kit, an innovative, automated positive blood culture sample preparation platform, for use with Bruker's MALDI Biotyper® CA System (MBT-CA System) and MBT-CA Sepsityper® software extension.
Accelerate Diagnostics (AXDX) is confident about WAVE product design and the system's capabilities after the successful completion of the pre-clinical trial.
Accelerate Diagnostics, Inc. (NASDAQ:AXDX ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Laura Pierson - Investor Relations Officer Jack Phillips - President and CEO David Patience - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Operator Good day. And welcome to the Accelerate Diagnostics Incorporated Second Quarter 2024 Results Conference Call.
Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $2.36 per share a year ago.
TUCSON, Ariz. , Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2024.
TUCSON, Ariz. , Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced that management will host a conference call today, Thursday, August 8, 2024, at 4:30 p.m.
- 1(current)
What type of business is Accelerate Diagnostics?
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
What sector is Accelerate Diagnostics in?
Accelerate Diagnostics is in the Healthcare sector
What industry is Accelerate Diagnostics in?
Accelerate Diagnostics is in the Medical Devices industry
What country is Accelerate Diagnostics from?
Accelerate Diagnostics is headquartered in United States
When did Accelerate Diagnostics go public?
Accelerate Diagnostics initial public offering (IPO) was on 07 April 1994
What is Accelerate Diagnostics website?
https://acceleratediagnostics.com
Is Accelerate Diagnostics in the S&P 500?
No, Accelerate Diagnostics is not included in the S&P 500 index
Is Accelerate Diagnostics in the NASDAQ 100?
No, Accelerate Diagnostics is not included in the NASDAQ 100 index
Is Accelerate Diagnostics in the Dow Jones?
No, Accelerate Diagnostics is not included in the Dow Jones index
When was Accelerate Diagnostics the previous earnings report?
No data
When does Accelerate Diagnostics earnings report?
The next expected earnings date for Accelerate Diagnostics is 28 March 2025